Value of Butyrylcholinesterase as a Marker of Surgical Site Infection Following Surgery for Colorectal Diseases

NCT04748744 COMPLETED

Butyrylcholinesterase (BChE) is an α-glycoprotein synthesized in the liver. BchE's serum level decreases in many clinical conditions such as acute and chronic liver damage, inflammation, injury and infections, and malnutrition. The Investigators prospectively evaluate patients undergoing elective procedures for colorectal diseases. Blood samples are collected preoperatively (at day 0), post-operatively in the recovery room (day 1), and on the subsequent four days (days 2, 3, 4, and 5) for assessment of BChE, C-reactive protein, and white blood cell concentrations. The same surgical team operates all patients and is blinded to the study. Patients are monitored for post-operative infection by using standard laboratory and clinical methods. If surgical site infection (SSI) is suspected the wound is swabbed and empirical antibiotics are started. The aim of the current trial is to study whether BChE is a reliable marker for the presence of SSI in patients undergoing colorectal surgery.

Details

Lead sponsor	University Hospital of Patras
Status	COMPLETED
Enrolment	400
Start date	Wed Nov 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon May 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Colorectal Disorders
• Colorectal Neoplasms

Interventions

• Butyrylcholinesterase

Countries

Greece